Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage
biopharmaceutical company developing a novel class of injectable
biologics to selectively engage and modulate disease-specific T
cells directly within the patient’s body, announced today two
poster presentations highlighting the company’s Immuno-STAT™
platform and lead clinical assets CUE-101 and CUE-102,
representative of the CUE-100 series, at the Society for
Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC
2023). The conference will be held in San Diego, California and
virtually on November 1-5, 2023.
Presentation
DetailsTitle: A phase 1 dose-escalation
and expansion study of CUE-101, given as monotherapy in 3L and in
combination with pembrolizumab in 1L recurrent/metastatic HPV16+
head and neck cancer patientsAbstract
Number: 674Presenter: Christine
Chung, M.D., H. Lee Moffitt Cancer Center, Tampa, Fla.
USADate: Saturday, November 4, 2023, Exhibit Halls
A and B1, 9 a.m.–8:30 p.m. PDT
Title: A phase 1 trial of CUE-102,
a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive
patients with WT1-positive recurrent/metastatic
cancersAbstract Number:
750Presenter: Jennifer Eva Selfridge, M.D., Ph.D.,
University Hospitals Cleveland Medical Center, Cleveland, OH,
USADate: Saturday, November 4, 2023, Exhibit Halls
A and B1, 9 a.m.–8:30 p.m. PDT
All posters will be available to conference
attendees as virtual e-posters on the virtual meeting platform
available November 3, 2023 at 9 am PDT through January 12, 2024.
The posters will also be available on November 4, 2023 in the
Investor & Media section of the Company’s website
at www.cuebiopharma.com, under Scientific
Publications and Presentations.
About the CUE-100
Series The CUE-100 series consists of Fc-fusion
biologics that incorporate peptide-MHC (pMHC) molecules along with
rationally engineered IL-2 molecules. This singular biologic is
anticipated to selectively target, activate and expand a robust
repertoire of tumor-specific T cells directly in the patient’s
body. The binding affinity of IL-2 for its receptor has been
deliberately attenuated to achieve preferential selective
activation of tumor-specific effector T cells while reducing the
potential for effects on regulatory T cells (Tregs) or broad
systemic activation, potentially mitigating the dose-limiting
toxicities associated with current IL-2-based therapies.
About SITCEstablished in 1984, the
Society for Immunotherapy of Cancer (SITC) is a nonprofit
organization of medical professionals dedicated to improving cancer
patient outcomes by advancing the development, science and
application of cancer immunotherapy and tumor immunology. SITC is
comprised of influential basic and translational scientists,
practitioners, health care professionals, government leaders and
industry professionals around the globe. Through educational
initiatives that foster scientific exchange and collaboration among
leaders in the field, SITC aims to one day make the word “cure” a
reality for cancer patients everywhere. Learn more about SITC
at sitcancer.org
About Cue BiopharmaCue
Biopharma, a clinical-stage biopharmaceutical company, is
developing a novel class of injectable biologics to selectively
engage and modulate disease-specific T cells directly within the
patient’s body. The company’s proprietary platform,
Immuno-STAT™ (Selective Targeting and Alteration of T
cells) and biologics are designed to harness the body’s
intrinsic immune system as T cell engagers without the need for ex
vivo manipulation or broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are
led by an experienced management team and independent Board of
Directors with deep expertise in immunology and immuno-oncology as
well as the design and clinical development of protein
biologics.
For more information please
visit www.cuebiopharma.com and follow us on Twitter
at https://twitter.com/CueBiopharma.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that are intended to be covered by the safe
harbor created by those sections. Such forward-looking statements
include, but are not limited to, those regarding: the company’s
plans to present data from its ongoing CUE-101 and CUE 102 clinical
trials; the company’s belief that the Immuno-STAT platform
stimulates targeted immune modulation through the selective
engagement of disease-relevant T cells; the company’s business
strategies, plans and prospects, including potential corporate
development opportunities; and the cash runway of the company and
the sufficiency of the company’s cash, cash equivalents, and
marketable securities to fund its operations. Forward-looking
statements, which are based on certain assumptions and describe the
company’s future plans, strategies and expectations, can generally
be identified by the use of forward-looking terms such as
“believe,” “expect,” “may,” “will,” “should,” “would,” “could,”
“seek,” “intend,” “plan,” “goal,” “project,” “estimate,”
“anticipate,” “strategy,” “future,” “likely” or other comparable
terms, although not all forward-looking statements contain these
identifying words. All statements other than statements of
historical facts included in this press release regarding the
company’s strategies, prospects, financial condition, operations,
costs, plans and objectives are forward-looking statements.
Important factors that could cause the company’s actual results and
financial condition to differ materially from those indicated in
the forward-looking statements include, among others, the company’s
limited operating history, limited cash and a history of losses;
the company’s ability to achieve profitability; potential setbacks
in the company’s research and development efforts including
negative or inconclusive results from its preclinical studies or
the company’s ability to replicate in later clinical trials
positive results found in preclinical studies and early-stage
clinical trials of its product candidates, its ability to secure
required U.S. Food and Drug Administration (“FDA”) or
other governmental approvals for its product candidates and the
breadth of any approved indication; adverse effects caused by
public health pandemics, including the recent COVID-19 pandemic,
including possible effects on the company’s trials; negative or
inconclusive results from the company’s clinical trials or
preclinical studies or serious and unexpected drug-related side
effects or other safety issues experienced by participants in
clinical trials; delays and changes in regulatory requirements,
policy and guidelines including potential delays in submitting
required regulatory applications to the FDA; the company’s reliance
on licensors, collaborators, contract research organizations,
suppliers and other business partners; the company’s ability to
obtain adequate financing to fund its business operations in the
future; operations and clinical the company’s ability to maintain
and enforce necessary patent and other intellectual property
protection; competitive factors; general economic and market
conditions and the other risks and uncertainties described in the
Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of the
company’s most recently filed Annual Report on Form 10-K and any
subsequently filed Quarterly Report(s) on Form 10-Q. Any
forward-looking statement made by the company in this press release
is based only on information currently available to the company and
speaks only as of the date on which it is made. The company
undertakes no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor ContactMarie
CampinellSenior Director, Corporate CommunicationsCue Biopharma,
Inc.mcampinell@cuebio.com
Media ContactMaya RomanchukLifeSci
Communicationsmromanchuk@lifescicomms.com
Cue Biopharma (NASDAQ:CUE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cue Biopharma (NASDAQ:CUE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024